EUVIMEDEUVIMED entdecken
Crossref

A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations

Zhenyu Yan, Lin Shi, Wei Li, Weihua Liu, Chad Galderisi, Cynthia Spittle, Jin Li

The Journal of Applied Laboratory Medicine · 2024

DOI: 10.1093/jalm/jfae096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Zhenyu Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICON Laboratory Services, ICON plc, Cambridge, MA, United States. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical management of chronic myeloid leukemia (CML) patients requires the identification of the type of BCR::ABL1 transcript at diagnosis and the monitoring of its expression and potential tyrosine kinase inhibitor (TKI) resistance mutations during treatment. Detection of resistant mutation requires transcript type-specific amplification of BCR::ABL1 from RNA.

Methods

In this study, a custom RNA-based next-generation sequencing (NGS) assay (Dup-Seq BCR::ABL1) that enables (a) the identification of BCR::ABL1 transcript type and (b) the detection of resistance mutations from common and atypical BCR::ABL1 transcript types was developed and validated. The assay design covers BCR exon 1 to ABL1 exon 10 and employs duplicate PCR amplification for error correction. The custom data analysis pipeline enables breakpoint determination and overlapped mutation calling from duplicates, which minimizes the low-level mutation artifacts.

Results

This study demonstrates that this novel assay achieves high accuracy (positive percent agreement (PPA) for fusion: 98.5%; PPA and negative percent agreement (NPA) for mutation at 97.8% and 100.0%, respectively) and sensitivity (limit of detection (LOD) for mutation detection at 3% from 10 000 copies of BCR::ABL1 input).

Conclusions

The Dup-Seq BCR::ABL1 assay not only allows for the identification of BCR::ABL1 typical and atypical transcript types and accurate and sensitive detection of TKI-resistant mutations but also simplifies molecular testing work flow for the clinical management of CML patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablDrug Resistance, NeoplasmMutationProtein Kinase InhibitorsHumansSensitivity and Specificity

Substanzen

Fusion Proteins, bcr-ablProtein Kinase Inhibitors

Autor:innen und Institutionen

  • ICON Laboratory Services, ICON plc, Cambridge, MA, United States.

Zitieren

APA

Yan, Z., Shi, L., Li, W., Liu, W., Galderisi, C., Spittle, C., & Li, J. (2024). A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae096

Vancouver

Yan Z, Shi L, Li W, Liu W, Galderisi C, Spittle C, et al. A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae096

BibTeX
@article{Yan2024,
  author = {Yan, Zhenyu and Shi, Lin and Li, Wei and Liu, Weihua and Galderisi, Chad and Spittle, Cynthia and Li, Jin},
  title = {A Novel Next-Generation Sequencing Assay for the Identification of BCR :: ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2024},
  doi = {10.1093/jalm/jfae096}
}
Kostenlos starten →